Singapore - engleză - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - alogliptin benzoate; pioglitazone hcl - tablet, film coated - alogliptin benzoate 12.5 mg; pioglitazone hcl 30 mg

Singapore - engleză - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - alogliptin benzoate; pioglitazone hcl - tablet, film coated - alogliptin benzoate 25 mg; pioglitazone hcl 15 mg

Singapore - engleză - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - alogliptin benzoate; pioglitazone hcl - tablet, film coated - alogliptin benzoate 25 mg; pioglitazone hcl 30 mg

Singapore - engleză - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - vonoprazan fumarate 13.36mg eqv vonoprazan - tablet, film coated - vonoprazan fumarate 13.36mg eqv vonoprazan 10mg

Singapore - engleză - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - vonoprazan fumarate 26.72mg eqv vonoprazan - tablet, film coated - vonoprazan fumarate 26.72mg eqv vonoprazan 20mg

Uniunea Europeană - engleză - EMA (European Medicines Agency)

takeda pharma a/s - azilsartan medoxomil - hypertension - agents acting on the renin-angiotensin system - ipreziv is indicated for the treatment of essential hypertension in adults.

Uniunea Europeană - engleză - EMA (European Medicines Agency)

takeda pharma a/s - pioglitazone hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - pioglitazone is indicated as second or third line treatment of type-2 diabetes mellitus as described below:as monotherapy:in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.as dual oral therapy in combination with:metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.after initiation of therapy with pioglitazone, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

Uniunea Europeană - engleză - EMA (European Medicines Agency)

takeda pharma a/s - ferumoxytol - anemia; kidney failure, chronic - other antianemic preparations - rienso is indicated for the intravenous treatment of iron-deficiency anaemia in adult patients with chronic kidney disease (ckd).the diagnosis of iron deficiency must be based on appropriate laboratory tests (see section 4.2).

Uniunea Europeană - engleză - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin, pioglitazone - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - incresync is indicated as a second- or third-line treatment in adult patients aged 18 years and older with type-2 diabetes mellitus: , as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on pioglitazone alone, and for whom metformin is inappropriate due to contraindications or intolerance;, in combination with metformin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on their maximal tolerated dose of metformin and pioglitazone. , in addition, incresync can be used to replace separate tablets of alogliptin and pioglitazone in those adult patients aged 18 years and older with type-2 diabetes mellitus already being treated with this combination. after initiation of therapy with incresync, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, incresync should be discontinued. in light of potential risks with prolonged pioglitazone therapy, prescribers should confirm at subsequent routine reviews that the benefit of incresync is maintained (see section 4.4).,

Uniunea Europeană - engleză - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - teduglutide - malabsorption syndromes - other alimentary tract and metabolism products, - revestive is indicated for the treatment of patients aged 1 year and above with short bowel syndrome (sbs). patients should be stable following a period of intestinal adaptation after surgery.revestive is indicated for the treatment of patients aged 1 year and above with short bowel syndrome. patients should be stable following a period of intestinal adaptation after surgery.